Position in GNLX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$52,814
+$22,472 QoQ
Shares Held
21,824
+94.2% QoQ
Ownership
0.049%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Catalyst Funds Management Pty Ltd holds $22,504,759 across 58 Biotechnology names. GNLX ranks #43 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
66,261 | $6,443,882 | |
| 2 | RPRX |
Royalty Pharma plc
|
79,147 | $3,796,681 | |
| 3 | MRNA |
Moderna, Inc.
|
55,363 | $2,812,440 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
11,200 | $763,056 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
25,031 | $693,358 | |
| 6 | QNCX |
Quince Therapeutics, Inc.
|
30,000 | $606,000 | |
| 7 | ABVX |
Abivax S.A.
|
5,000 | $556,750 | |
| 8 | NKTR |
Nektar Therapeutics
|
6,700 | $482,065 |
All Filings in GNLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $52,814 | 21,824 | Shares | Sole | 2026-05-11 | |
| 2025-03-31 | $30,342 | 11,238 | Shares | Sole | 2025-05-14 | |
| 2024-09-30 | $11,376 | 4,800 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $9,360 | 4,800 | Shares | Sole | 2024-12-18 | |
| No filing history on record for this holder in this stock. | ||||||